1. EMPA-REG OUTCOME: The Endocrinologist's Point of View
Leigh Perreault, MD 
The American Journal of Medicine 
Volume 130, Issue 6, Pages S51-S56 (June 2017)
DOI: /j.amjmed
Copyright © 2017 The Author Terms and Conditions

2. Figure
Schematic representation of the potential metabolic and hemodynamic pathways responsible for the reduction in mortality and hospitalization for heart failure observed with empagliflozin in EMPA-REG OUTCOME.19 American Diabetes Association “SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.” American Diabetes Association, 2016 Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. Ang 1-7 = angiotensin 1-7; AT2 = angiotensin 2 receptor; ECFV = extracellular fluid volume; FFA = free fatty acids.
The American Journal of Medicine  , S51-S56DOI: ( /j.amjmed )
Copyright © 2017 The Author Terms and Conditions